Literature DB >> 9820934

Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and the treatment of glaucoma.

T J Liesegang1.   

Abstract

PURPOSE: Enhance recognition by the external disease specialist of the conjunctival changes associated with glaucoma therapy and the reported association with glaucoma filtration surgery.
METHODS: Literature search with emphasis on the cellular and subcellular changes induced by antiglaucoma medications, the definition and diagnosis of drug-induced cicatricial conjunctivitis (DICC), and the implications for future glaucoma therapy or surgery.
RESULTS: Significant conjunctival and subconjunctival changes occur associated with the use of antiglaucoma medications that affect the success of glaucoma filtration surgery. The extreme form of change is the DICC, which is clinically and pathologically identical to ocular cicatricial pemphigoid. The autoantigen in the basement membrane probably differs in these two disease processes.
CONCLUSIONS: There is a movement toward an earlier approach to glaucoma filtration surgery, in large part based on the literature reviewed here. The external disease specialist needs to be cognizant of these conjunctival changes to best consult on patients receiving antiglaucoma medications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820934     DOI: 10.1097/00003226-199811000-00001

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  9 in total

Review 1.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

2.  Corneal graft rejection 10 years after penetrating keratoplasty in the cornea donor study.

Authors:  Steven P Dunn; Robin L Gal; Craig Kollman; Dan Raghinaru; Mariya Dontchev; Christopher L Blanton; Edward J Holland; Jonathan H Lass; Kenneth R Kenyon; Mark J Mannis; Shahzad I Mian; Christopher J Rapuano; Walter J Stark; Roy W Beck
Journal:  Cornea       Date:  2014-10       Impact factor: 2.651

3.  Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study.

Authors:  Shashi Kumar Bhasker; Sandeep Saxena; Kamlesh Singh
Journal:  J Ocul Biol Dis Infor       Date:  2013-06-27

4.  Prostaglandin E2 and F2α Alter Expression of Select Cholesteryl Esters and Triacylglycerols Produced by Human Meibomian Gland Epithelial Cells.

Authors:  Jillian F Ziemanski; Landon Wilson; Stephen Barnes; Kelly K Nichols
Journal:  Cornea       Date:  2022-01-01       Impact factor: 3.152

5.  Short-term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects.

Authors:  Naim Terai; Matthias Müller-Holz; Eberhard Spoerl; Lutz E Pillunat
Journal:  Clin Ophthalmol       Date:  2011-04-26

6.  Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension.

Authors:  Sophia K Mirza; Sandra M Johnson
Journal:  Clin Ophthalmol       Date:  2010-08-09

7.  Tolerability and effectiveness of preservative-free dorzolamide-timolol (preservative-free COSOPT) in patients with open-angle glaucoma or ocular hypertension.

Authors:  Cindy Hutnik; David Neima; Fahim Ibrahim; Robert Scott; Julie Vaillancourt; Denis Haine; John S Sampalis; Natacha Bastien; Sylvain Foucart
Journal:  Clin Ophthalmol       Date:  2010-07-21

8.  Prospective unmasked randomized evaluation of the iStent inject (®) versus two ocular hypotensive agents in patients with primary open-angle glaucoma.

Authors:  Antonio M Fea; Jose I Belda; Marek Rękas; Anselm Jünemann; Lydia Chang; Luis Pablo; Lilit Voskanyan; L Jay Katz
Journal:  Clin Ophthalmol       Date:  2014-05-07

Review 9.  Preservatives in glaucoma medication.

Authors:  David W Steven; Pouya Alaghband; Kin Sheng Lim
Journal:  Br J Ophthalmol       Date:  2018-07-04       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.